Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SPRITAM vs KEPPRA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Spritam is a levetiracetam formulation; levetiracetam binds to synaptic vesicle glycoprotein 2A (SV2A) to modulate neurotransmitter release, reducing neuronal excitability.
Levetiracetam binds to synaptic vesicle protein 2A (SV2A), modulating neurotransmitter release and reducing neuronal hyperexcitability. It also inhibits high-voltage N-type calcium channels and reduces GABAergic and glycinergic inhibition.
Adjunctive therapy for partial-onset seizures,Myoclonic seizures in JME,Primary generalized tonic-clonic seizures
Adjunctive therapy for partial-onset seizures (FDA),Adjunctive therapy for myoclonic seizures in juvenile myoclonic epilepsy (FDA),Adjunctive therapy for primary generalized tonic-clonic seizures (FDA),Off-label: Bipolar disorder, migraine prophylaxis, neuropathic pain, status epilepticus
SPRITAM is not a standard formulation; levetiracetam immediate-release: 500 mg PO BID, titrated to 1000 mg PO BID (max 1500 mg PO BID). For extended-release (Keppra XR): 1000 mg PO once daily, titrated to 2000 mg PO once daily.
500 mg orally twice daily, titrated up to 1500 mg twice daily as tolerated.
Terminal half-life: 6–8 hours; clinical context: requires twice-daily dosing for stable serum concentrations
6-8 hours in adults; prolonged to 10-18 hours in renal impairment (Cr Cl <30 m L/min); clinical context: dosing interval adjustment required in renal disease.
Hydrolysis by esterases in blood and tissues to carboxylic acid metabolite (ucb L057); not CYP450 dependent.
Levetiracetam is not extensively metabolized; ~66% of the dose is excreted unchanged in urine. Metabolism occurs via enzymatic hydrolysis of the acetamide group, independent of cytochrome P450. Major metabolite is the carboxylic acid derivative (ucb L057), which is pharmacologically inactive.
Renal: 66% unchanged; hepatic metabolism: 24% (inactive metabolites); fecal: negligible (<1%)
Renal: 66% unchanged; 27% as inactive metabolite; 0.3% fecal.
<10% bound; primarily to albumin (minimal binding)
<10% bound to plasma proteins (albumin).
0.7–1.1 L/kg; approximates total body water, indicating extensive distribution into tissues
0.5-0.7 L/kg; approximates total body water; clinical meaning: extensive distribution into tissues, including brain.
Oral immediate-release: 100%; oral extended-release: approximately 100% relative to immediate-release
Oral: 100% (immediate-release formulation); IV: 100%.
Cr Cl >80 m L/min: 500-1500 mg BID (IR) or 1000-2000 mg once daily (XR); Cr Cl 50-80: 500-1000 mg BID (IR) or 1000-2000 mg once daily (XR); Cr Cl 30-50: 250-750 mg BID (IR) or 500-1500 mg once daily (XR); Cr Cl <30: 250-500 mg BID (IR) or 500-1000 mg once daily (XR); ESRD on dialysis: 500-1000 mg once daily (IR) with supplemental dose after dialysis.
Cr Cl 50-80 m L/min: 500-1000 mg every 12 hours; Cr Cl 30-49 m L/min: 250-750 mg every 12 hours; Cr Cl <30 m L/min: 250-500 mg every 12 hours; ESRD on dialysis: 500-1000 mg once daily with 250-500 mg supplemental dose after dialysis.
Mild to moderate hepatic impairment (Child-Pugh A or B): no dose adjustment required; severe hepatic impairment (Child-Pugh C): use with caution; no specific dose reduction recommended, but monitor for adverse effects.
No specific adjustment for hepatic impairment; use caution in severe hepatic impairment.
For immediate-release: age 1 month to <6 months: 7 mg/kg/dose BID initially, titrate to 21 mg/kg/dose BID; age 6 months to <4 years: 10 mg/kg/dose BID initially, titrate to 25 mg/kg/dose BID; age 4 to <16 years: 10 mg/kg/dose BID initially, titrate up to 30 mg/kg/dose BID (max 1500 mg/day). For extended-release: only for ≥12 years: 1000 mg once daily initially, titrate to 2000 mg once daily.
1 month to <6 months: 7 mg/kg twice daily, titrate to 21 mg/kg twice daily; 6 months to <4 years: 10 mg/kg twice daily, titrate to 25 mg/kg twice daily; 4 to <16 years: 10 mg/kg twice daily, titrate to 30 mg/kg twice daily (maximum 3000 mg/day).
Consider age-related renal impairment; adjust dose based on Cr Cl per renal adjustment. Start at lower end of dosing range; monitor for sedation, dizziness, and falls.
Start at 250-500 mg twice daily; titrate slowly due to age-related renal function decline.
No FDA black box warning.
None
Behavioral abnormalities (psychosis, aggression, suicidal ideation),Somnolence and fatigue,Dermatological reactions (e.g., Stevens-Johnson syndrome),Hematologic abnormalities,Withdrawal seizures on abrupt discontinuation
Behavioral and psychiatric symptoms: psychosis, aggression, suicidal ideation,Somnolence and fatigue, dose-dependent,Stevens-Johnson syndrome and toxic epidermal necrolysis (rare),Hematologic abnormalities: decreased red blood cell, white blood cell, and platelet counts,Acute kidney injury (rare), intercurrent illness may increase risk,Avoid abrupt discontinuation to minimize seizure exacerbation or status epilepticus
Hypersensitivity to levetiracetam or any component of Spritam
Hypersensitivity to levetiracetam or any of its components
No significant food interactions. SPRITAM can be taken with or without food. A high-fat meal may slightly delay absorption but does not affect overall exposure. Avoid grapefruit juice? Not required; no known interaction with grapefruit. Alcohol may potentiate CNS depression and should be avoided.
No significant food interactions. Levetiracetam absorption is not affected by food. Avoid alcohol as it may increase CNS depression.
Spritam (levetiracetam) is classified as Pregnancy Category C. In the first trimester, there is an increased risk of major congenital malformations, including neural tube defects, when used in polytherapy, but monotherapy may have a lower risk. Data from human pregnancy registries suggest a risk of major birth defects of 1.5-2.4% with monotherapy, compared to a baseline risk of 2-4%. In the second and third trimesters, exposure may lead to decreased fetal growth and transient neonatal effects such as sedation, withdrawal symptoms, and hypotonia. Levetiracetam is not highly protein-bound and crosses the placenta with a cord-to-maternal plasma ratio close to 1.
Increased risk of major congenital malformations, particularly neural tube defects (e.g., spina bifida), cleft palate, and cardiovascular defects, especially with first trimester exposure. Risk is dose-dependent and higher with polytherapy. Second and third trimester exposure may be associated with neurodevelopmental impairments.
Levetiracetam is excreted into human breast milk with a milk-to-plasma (M/P) ratio of approximately 1.0. Relative infant dose is about 1-3% of maternal weight-adjusted dose, which is considered low. Limited data suggest no adverse effects on infant development. However, due to potential for lethargy and poor feeding, breastfeeding should be monitored. The benefits of breastfeeding likely outweigh risks for most infants.
Levetiracetam is excreted into breast milk with an M/P ratio of approximately 1.0. Infant serum levels are about 10-30% of maternal levels. Generally considered compatible with breastfeeding, but monitor infant for drowsiness, poor feeding, and developmental milestones.
Pregnancy can alter levetiracetam pharmacokinetics, with increased clearance and reduced serum concentrations in the second and third trimesters. Dose adjustments may be necessary to maintain seizure control. Therapeutic drug monitoring is recommended, with target trough levels at the lower end of the therapeutic range (12-46 mcg/m L) to minimize fetal exposure while ensuring efficacy. Postpartum, clearance returns to baseline, and doses should be reduced accordingly.
Pregnancy increases levetiracetam clearance by 30-60%, especially in the second and third trimesters. Monitor serum trough concentrations every 1-2 months and increase dose as needed to maintain therapeutic levels. Postpartum, reduce dose to pre-pregnancy levels within the first week.
SPRITAM (levetiracetam) is a racetam anticonvulsant with a unique mechanism of action (SV2A binding). It exhibits linear pharmacokinetics with rapid oral absorption. No therapeutic drug monitoring required due to wide therapeutic index. Adjust dose in renal impairment (Cr Cl <80 m L/min). Free fraction of levetiracetam is not affected by hepatic impairment. Titrate slowly to reduce CNS side effects (somnolence, dizziness). Abrupt discontinuation may increase seizure frequency. Available in immediate-release tablets.
Levetiracetam (Keppra) is a broad-spectrum AED with minimal drug interactions. Dosing must be adjusted for renal function (Cr Cl <80 m L/min). Monitor for behavioral changes, especially in pediatric patients. IV formulation can be administered without ECG monitoring. No need for therapeutic drug monitoring; efficacy and tolerability guide dosing.
Take SPRITAM exactly as prescribed; do not stop suddenly.,May cause dizziness or drowsiness; avoid driving until effects are known.,Monitor for mood changes, depression, or suicidal thoughts.,Report any skin rash or signs of allergic reaction immediately.,Use reliable contraception if applicable (no known major interaction with hormonal contraceptives).,Swallow tablets whole; do not crush or chew.,Store at room temperature, away from moisture.
Take exactly as prescribed; do not stop suddenly as withdrawal seizures may occur.,Report any unusual mood changes, depression, or aggressive behavior to your doctor.,May cause dizziness or drowsiness; avoid driving until effects are known.,Take with or without food; do not crush extended-release tablets.,Drink plenty of fluids to prevent kidney stones, though not a common side effect.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SPRITAM vs KEPPRA, answered by our medical review team.
SPRITAM is a Antiepileptic that works by Spritam is a levetiracetam formulation; levetiracetam binds to synaptic vesicle glycoprotein 2A (SV2A) to modulate neurotransmitter release, reducing neuronal excitability.. KEPPRA is a Antiepileptic that works by Levetiracetam binds to synaptic vesicle protein 2A (SV2A), modulating neurotransmitter release and reducing neuronal hyperexcitability. It also inhibits high-voltage N-type calcium channels and reduces GABAergic and glycinergic inhibition.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SPRITAM and KEPPRA depend on the specific clinical indication. These are both Antiepileptic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SPRITAM is: SPRITAM is not a standard formulation; levetiracetam immediate-release: 500 mg PO BID, titrated to 1000 mg PO BID (max 1500 mg PO BID). For extended-release (Keppra XR): 1000 mg PO once daily, titrated to 2000 mg PO once daily.. The standard adult dose of KEPPRA is: 500 mg orally twice daily, titrated up to 1500 mg twice daily as tolerated.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SPRITAM and KEPPRA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SPRITAM is classified as Category C. Spritam (levetiracetam) is classified as Pregnancy Category C. In the first trimester, there is an increased risk of major congenital malformations, including neural tube defects, . KEPPRA is classified as Category C. Increased risk of major congenital malformations, particularly neural tube defects (e.g., spina bifida), cleft palate, and cardiovascular defects, especially with first trimester e. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.